Cargando…

Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review

Background and Purpose: The mechanism of action of Batroxobin included the decomposition of the fibrinogen to fibrin degradation products (FDPs) and D-dimer and mobilization of endothelial cells to release endogenous nt-PA and to promote thrombolysis. This review aims to summarize current study find...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Duo, Song, Siying, Liu, Yunhuan, Jiao, Baolian, Meng, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675357/
https://www.ncbi.nlm.nih.gov/pubmed/34925203
http://dx.doi.org/10.3389/fneur.2021.716778
_version_ 1784615857550262272
author Lan, Duo
Song, Siying
Liu, Yunhuan
Jiao, Baolian
Meng, Ran
author_facet Lan, Duo
Song, Siying
Liu, Yunhuan
Jiao, Baolian
Meng, Ran
author_sort Lan, Duo
collection PubMed
description Background and Purpose: The mechanism of action of Batroxobin included the decomposition of the fibrinogen to fibrin degradation products (FDPs) and D-dimer and mobilization of endothelial cells to release endogenous nt-PA and to promote thrombolysis. This review aims to summarize current study findings about batroxobin on correcting cerebral arterial, venous, and peripheral vascular diseases, to explore the mechanism of batroxobin on anti-thrombosis process. Methods: A thorough literature search was conducted utilizing the PubMed Central (PMC) and EMBASE databases to identify studies up to June 2021. Data from clinical studies and animal experiments about batroxobin were extracted, integrated and analyzed based on Cochrane handbook for systematic reviews of interventions approach and the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P), including the condition of subjects, the usage and dosage, research observation index and main findings. Results: A total of 62 studies were enrolled in this systematic review, including 26 clinical studies and 36 animal experiments. The 26 clinical studies involved 873 patients with arterial ischemic events, 92 cases with cerebral venous thrombosis, 13 cases with cerebral cortical vein thrombosis, and 1,049 cases with peripheral vascular diseases. These patients included 452 males and 392 females aged 65.6 ± 5.53 years. The results revealed that batroxobin had broad effects, including improving clinical prognosis (n = 12), preventing thrombosis (n = 7), promoting thrombolysis (n = 6), and improving vascular cognitive dysfunction (n = 1). The effects of batroxobin on reducing neuronal apoptosis (n = 8),relieving cellular edema (n = 4), improving spatial memory (n = 3), and promoting thrombolysis (n = 13) were concluded in animal experiments. The predominant mechanisms explored in animal experiments involved promoting depolymerization of fibrinogen polymers (n = 6), regulating the expression of related molecules (n = 9); such as intercellular adhesion molecule, heat shock proteins, tumor necrosis factor), reducing oxidative stress (n = 5), and reducing inflammation response (n = 4). Conclusion: Batroxobin can correct both arterial and venous ischemic diseases by promoting depolymerization of fibrinogen polymers, regulating the expression of related molecules, reducing oxidative stress, and reducing the inflammation response.
format Online
Article
Text
id pubmed-8675357
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86753572021-12-17 Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review Lan, Duo Song, Siying Liu, Yunhuan Jiao, Baolian Meng, Ran Front Neurol Neurology Background and Purpose: The mechanism of action of Batroxobin included the decomposition of the fibrinogen to fibrin degradation products (FDPs) and D-dimer and mobilization of endothelial cells to release endogenous nt-PA and to promote thrombolysis. This review aims to summarize current study findings about batroxobin on correcting cerebral arterial, venous, and peripheral vascular diseases, to explore the mechanism of batroxobin on anti-thrombosis process. Methods: A thorough literature search was conducted utilizing the PubMed Central (PMC) and EMBASE databases to identify studies up to June 2021. Data from clinical studies and animal experiments about batroxobin were extracted, integrated and analyzed based on Cochrane handbook for systematic reviews of interventions approach and the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P), including the condition of subjects, the usage and dosage, research observation index and main findings. Results: A total of 62 studies were enrolled in this systematic review, including 26 clinical studies and 36 animal experiments. The 26 clinical studies involved 873 patients with arterial ischemic events, 92 cases with cerebral venous thrombosis, 13 cases with cerebral cortical vein thrombosis, and 1,049 cases with peripheral vascular diseases. These patients included 452 males and 392 females aged 65.6 ± 5.53 years. The results revealed that batroxobin had broad effects, including improving clinical prognosis (n = 12), preventing thrombosis (n = 7), promoting thrombolysis (n = 6), and improving vascular cognitive dysfunction (n = 1). The effects of batroxobin on reducing neuronal apoptosis (n = 8),relieving cellular edema (n = 4), improving spatial memory (n = 3), and promoting thrombolysis (n = 13) were concluded in animal experiments. The predominant mechanisms explored in animal experiments involved promoting depolymerization of fibrinogen polymers (n = 6), regulating the expression of related molecules (n = 9); such as intercellular adhesion molecule, heat shock proteins, tumor necrosis factor), reducing oxidative stress (n = 5), and reducing inflammation response (n = 4). Conclusion: Batroxobin can correct both arterial and venous ischemic diseases by promoting depolymerization of fibrinogen polymers, regulating the expression of related molecules, reducing oxidative stress, and reducing the inflammation response. Frontiers Media S.A. 2021-12-02 /pmc/articles/PMC8675357/ /pubmed/34925203 http://dx.doi.org/10.3389/fneur.2021.716778 Text en Copyright © 2021 Lan, Song, Liu, Jiao and Meng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Lan, Duo
Song, Siying
Liu, Yunhuan
Jiao, Baolian
Meng, Ran
Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
title Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
title_full Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
title_fullStr Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
title_full_unstemmed Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
title_short Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
title_sort use of batroxobin in central and peripheral ischemic vascular diseases: a systematic review
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675357/
https://www.ncbi.nlm.nih.gov/pubmed/34925203
http://dx.doi.org/10.3389/fneur.2021.716778
work_keys_str_mv AT landuo useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview
AT songsiying useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview
AT liuyunhuan useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview
AT jiaobaolian useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview
AT mengran useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview